HTB

Benefit of maintaining the M184V mutation with 3TC monotherapy: final 48-week results

14 September 2005. Related: Conference reports, Antiretrovirals, .

Simon Collins, HIV i-Base

Final results were presented from the E-184V study [1] whose interim results were presented at the Bangkok conference last year and at this year Resistance Workshop in Quebec. [2, 3]

Castagna and colleagues from Vita-Salute San Raffaele University in Milan randomised 58 patients with viral rebound on 3TC-containing regimens and confirmed M184V resistance and who wanted to take a treatment interruption, to either discontinue all treatment or to maintain 3TC monotherapy. All patients had CD4 counts >500 cells/mm3.

After 48 weeks, the group that continued taking 3TC had a reduced viral load rebound (+0.57 versus +1.11 log10 copies/mL) and a smaller drop in CD4 count (-141 versus -215 cells/mm3) compared to the group that stopped all treatment. 12/29 (41%) in the 3TC group vs 20/29 (69%) in the treatment interruption group experienced protocol defined failure (development of HIV-related symptoms or CD4 count <350 cells/mm3.

Maintaining M184V mutation was associated with reduced viral replicative capacity in patients taking 3TC monotherapy. There were no difference in the virological and CD4 responses between patients in each group who needed to restart treatment.

Comment

These 48-week results confirm previous analyses from this important study. [2, 3]

Although this will be a very useful option though for people are considering stopping treatment who already have the M184V mutation, the importance of this study is probably less to do with the benefits of 3TC monotherapy.

The virological benefit from maintaining M184V potentially suggests use of 3TC as an additional active drug in salvage therapy, and has provided evidence (through a different trial design) that the Colate study (which was closed after three years by the DSMB due to poor enrolment) was never able to achieve. [4]

FTC has cross-resistance with 3TC because of a similar relationship to the M184V mutation, and would be expected to produce similar results to 3TC in this study. The impact of using abacavir for this strategy has not been studied.

Reference:

  1. Castagna A, Danise A, Menzo S et al. E-184V study. Lamivudine monotherapy vs treatment interruption in failing HIV-1 infected subjects, harbouring the M184V mutation: 48-week final results. 3rd IAS Conference on HIV Pathogenesis and Treatment, Rio de Janeiro, 2005. Abstract WeFo0204.
  2. Gianotti E, Menzo S, Danise A et al. E-184V study: immunological and virological correlates of HIV-1 replicative capacity. 14th HIV Drug Resistance Workshop, 7-11 June 2005, Quebec City, Canada. Abstract 160. HIV Treatment Bulletin. Vol6 No7. July 2005.
    http://www.i-base.info/htb/7130/
  3. Castagna et al. E184V – International AIDS Conference, Bangkok, 2004. (Abstract WeOrB1286. HIV Treatment Bulletin. Vol5 No7. August/September 2004.
    http://www.i-base.info/htb/7125/
  4. COLATE study shows no clinical benefit from continuing 3TC to maintain M184V mutation. HIV Treatment Bulletin Vol5 No3. April 2004.
    http://www.i-base.info/htb/7122/

Links to other websites are current at date of posting but not maintained.